Published Study Finds That More Than One-Third of Patients With Type 2 Diabetes Also Suffer From Obstructive Sleep Apnea
Posted on: Tuesday, 31 July 2007, 12:03 CDT
Study results published in the current issue of Endocrine Practice suggest that patients with type 2 diabetes are at an increased risk for obstructive sleep apnea (OSA).
The study - conducted at The Whittier Institute for Diabetes (La Jolla, Calif.) under the supervision of Principal Investigator Daniel Einhorn, M.D. - evaluated a patient population of 279 adults with type 2 diabetes and found that 36 percent of these patients also suffered from OSA. In 2005, a published study found that patients with OSA and type 2 diabetes who were treated with continuous positive airway pressure (CPAP) therapy experienced a significant reduction in glucose levels (Archives of Internal Medicine, 2005; 165: 447-452).
"These findings demonstrate that obstructive sleep apnea has a high prevalence in adults with type 2 diabetes," said Dr. Einhorn. "Given that treatment of obstructive sleep apnea has the potential to both decrease blood pressure and improve glycemic control, individuals with type 2 diabetes should be regularly screened for the presence of sleep apnea."
What: Published study results find that 36 percent of patients with type 2 diabetes also suffer from obstructive sleep apnea (OSA).
Who: Principal Investigator of the study, Daniel Einhorn, M.D.
Where: The Whittier Institute for Diabetes (a subsidiary of Scripps Health), located in La Jolla, Calif.
When: Study results to be published in the current issue of Endocrine Practice
Source: Business Wire
Related Articles
- Vitro Diagnostics Wins Approval for Diabetes Study Protocol
- Vitro Receives Approval for Preclinical Diabetes Study Protocol
- BTG Reports Positive Results From First Study Investigating BGC20-0166 in Obstructive Sleep Apnoea Patients
- Death Risk Halts Diabetes Study
- Nektar Reports Pfizer Announcement That New Studies Show More Than Half of Patients at Risk for or Suffering From Complications of Type 2 Diabetes Delay Insulin Injections -- Some More Than Four Years
- Diabetes Study Called Partial Success
- Positive Data From Type 1 Diabetes Study of TolerRx's TRX4 Published in the New England Journal of Medicine
- Lisofylline in Combination With Exendin-4 Reverses Diabetes in a Type 1 Model; LSF and GLP-1 Treatment Also Improved Islet Cell Viability and Normalized Insulin Secretion
- Determinants of Diabetes-Attributable Non-Blood Glucose-Lowering Medication Costs in Type 2 Diabetes: The Fremantle Diabetes Study
- The CARDS Investigators: Primary Prevention of Cardiovascular Disease With Atorvastatin in Type 2 Diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre Randomised Placebo- Controlled Trial
 |
 |
User Comments (0)
RSS Feeds